FDA Brief

Warning letters Drugs

FDA warning letter to

Revlon Group Holdings, LLC

High riskIssued Jun 2Posted Jun 9Center for Drug Evaluation and Research (CDER)

FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

What happened

FDA reviewed records Revlon submitted after a September 8, 2025 records request and later correspondence for its Oxford, NC facility. FDA said the company did not show it tests talc for asbestos, relied on supplier test results without validating them, used an incomplete identity test, and let its quality unit accept talc with deficient specifications. FDA called these significant violations of current good manufacturing practice (CGMP), the required quality rules for drug manufacturing.

What FDA found

  1. Revlon did not test incoming talc for asbestos and did not show that its supplier's asbestos test results were reliable.

    21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)
  2. Revlon's identity test for talc was incomplete because it lacked United States Pharmacopeia (USP) identification B and C.

    21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)
  3. Revlon's quality unit accepted talc with deficient specifications, including a yeast and mold limit above the USP limit and certificate of analysis (COA) results that said only CONFORM.

    21 CFR 211.22 and 21 CFR 211.160(b)
  4. Revlon released multiple OTC drug lots within a few months of expiry, including one with only one month left.

  5. Revlon's talc specifications were incomplete compared with the current USP talc monograph, including the asbestos test.

    section 501(b) of the FD&C Act

What FDA wants

FDA tells Revlon to correct the violations promptly and respond in writing within 15 working days with corrective actions. It also asks for talc/asbestos test results within 30 calendar days, a risk assessment and recall or customer notification if needed, supplier-test validation and USP gap plans, quality-unit remediation, and a reformulation update.

Who should pay attention

  • companies that buy or distribute Revlon OTC drug products containing talc
  • talc suppliers and contract manufacturers making drug components
  • quality teams that rely on supplier certificates of analysis for release

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk